Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Management of Hepatitis C Infection

Stefan Zeuzem, MD
Program Director
Jordan J. Feld, MD, MPH
Hemant Shah, MD, MScCH HPTE
Released: June 17, 2019
Back Next

Introduction

The goal of antiviral therapy for patients with HCV is virologic cure. Eradication of HCV RNA, which remains undetectable long term off therapy, is referred to as a sustained virologic response and is now an increasingly achievable prospect thanks to the availability of direct-acting antivirals (DAAs). Several new classes of DAAs have been approved for the treatment of chronic HCV infection during the last 4 years, leading to dramatic shifts in the HCV landscape. This module focuses on evidence-based management approaches for patients with HCV infection, including treatment of patients with cirrhosis, strategies for drug resistance, and posttreatment management.

Back Next

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings